US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

COYA THERAPEUTICS INC

5.71

+0.45008.56%

Volume:181.99K

Turnover:1.02M

Market Cap:95.50M

PE:-5.85

High:5.92

Open:5.19

Low:5.06

Close:5.26

Loading ...

Overview Company News Filings

Coya Therapeutics announces publication of study results on COYA 303

Coya Therapeutics Announces Publication of Glp-1/Ld Il-2 Combination Biologic (Coya 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)

THOMSON REUTERS

Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)

BRIEF-Atea Pharmaceuticals Appoints Howard H. Berman To Board Of Directors And Announces Share Repurchase Program

Atea Pharmaceuticals Inc: Authorized Repurchase of up to $25 Mln of Company's Common Stock

THOMSON REUTERS

Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

THOMSON REUTERS

Press Release: Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

Is Coya Therapeutics (COYA) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?

Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025

What Makes Coya Therapeutics, Inc. (COYA) a New Buy Stock

Are Medical Stocks Lagging Auna S.A. (AUNA) This Year?

Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program

Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.

Calendar of U.S. Earnings Expected in the Week Ahead

Press Release: Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results

Analysts’ Top Healthcare Picks: Coya Therapeutics, Inc. (COYA), Jasper Therapeutics (JSPR)

Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing

Coya Therapeutics up 8% on Positive Results From Mid-Stage Alzheimer’s Disease Trial

THOMSON REUTERS

Coya Therapeutics Is Maintained at Buy by D. Boral Capital

BRIEF-Coya Therapeutics Inc Reports Significant Improvement In Inflammatory Markers In Alzheimer's Patients

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/COYA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"COYA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"COYA\",,,,,undefined,":{"symbol":"COYA","market":"US","secType":"STK","nameCN":"COYA THERAPEUTICS INC","latestPrice":5.71,"timestamp":1745265600000,"preClose":5.26,"halted":0,"volume":181990,"delay":0,"floatShares":12564296,"shares":16724998,"eps":-0.976498,"marketStatus":"Pre-Mkt","change":0.45,"latestTime":"04-22 04:22:18 EDT","open":5.19,"high":5.92,"low":5.0595,"amount":1019455.02091,"amplitude":0.163593,"askPrice":6.9,"askSize":100,"bidPrice":4.21,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-0.976498,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1745328600000},"marketStatusCode":1,"adr":0,"listingDate":1672290000000,"exchange":"NASDAQ","adjPreClose":5.71,"postHourTrading":{"tag":"盘后","latestPrice":5.71,"preClose":5.71,"latestTime":"19:57 EDT","volume":202,"amount":1226.63,"timestamp":1745279865261},"volumeRatio":2.9943320596839533},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"COYA\",,,,,undefined,":{"symbol":"COYA","floatShares":12564296,"roa":"-25.15%","roe":"-39.57%","lyrEps":-0.976498,"volumeRatio":2.9943320596839533,"shares":16724998,"dividePrice":0,"high":5.92,"amplitude":0.163593,"preClose":5.26,"low":5.0595,"week52Low":4.65,"pbRate":"2.41","psRate":"26.87","week52High":10.24,"institutionHeld":0,"latestPrice":5.71,"eps":-0.976498,"divideRate":0,"volume":181990,"delay":0,"ttmEps":-0.976498,"open":5.19,"prevYearClose":5.73,"prevWeekClose":5.26,"prevMonthClose":6.47,"prevQuarterClose":6.47,"fiveDayClose":5.17,"twentyDayClose":6.68,"sixtyDayClose":5.84},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"COYA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2529807540","title":"Coya Therapeutics announces publication of study results on COYA 303","url":"https://stock-news.laohu8.com/highlight/detail?id=2529807540","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529807540?lang=en_us&edition=fundamental","pubTime":"2025-04-21 21:55","pubTimestamp":1745243710,"startTime":"0","endTime":"0","summary":"Coya Therapeutics (COYA) announced publication of the results of a study designed to evaluate the effects of COYA 303, Coya’s investigational biolo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/coya-therapeutics-announces-publication-of-study-results-on-coya-303?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/coya-therapeutics-announces-publication-of-study-results-on-coya-303?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["COYA","BK4139"],"gpt_icon":0},{"id":"2529802401","title":"Coya Therapeutics Announces Publication of Glp-1/Ld Il-2 Combination Biologic (Coya 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)","url":"https://stock-news.laohu8.com/highlight/detail?id=2529802401","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529802401?lang=en_us&edition=fundamental","pubTime":"2025-04-21 21:51","pubTimestamp":1745243460,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250421:nTUA8MNVJH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","COYA"],"gpt_icon":0},{"id":"2529807972","title":"Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)","url":"https://stock-news.laohu8.com/highlight/detail?id=2529807972","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529807972?lang=en_us&edition=fundamental","pubTime":"2025-04-21 21:51","pubTimestamp":1745243460,"startTime":"0","endTime":"0","summary":"COYA 303 is an investigational biologic combination of COYA 301, Coya’s low-dose interleukin 2  and a GLP-1 receptor agonist , designed to deliver a multi-targeted immunomodulatory therapeutic in autoimmune and neurodegenerative diseases. COYA 303 produced a statistically significantly higher Treg suppressive effect on pro-inflammatory myeloid cells and enhanced Treg survival in in vitro human immune cells, compared to the individual components - LD IL-2 and GLP-1RA. Dr. Fred Grossman, Coya’s Chief Medical Officer commented, \"We believe the encouraging results of this study provide support for our multi-targeted combination approach as a potentially viable treatment option for serious and life-threatening conditions of high unmet need driven by chronic inflammation and Treg dysfunction, for which currently av","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/coya-therapeutics-announces-publication-glp-135100483.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GLP","LD","COYA"],"gpt_icon":0},{"id":"2528179095","title":"BRIEF-Atea Pharmaceuticals Appoints Howard H. Berman To Board Of Directors And Announces Share Repurchase Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2528179095","media":"Reuters","labels":["executive","shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528179095?lang=en_us&edition=fundamental","pubTime":"2025-04-17 19:05","pubTimestamp":1744887914,"startTime":"0","endTime":"0","summary":"BRIEF-Atea Pharmaceuticals Appoints Howard H. Berman To Board Of Directors And Announces Share Repurchase ProgramApril 17 (Reuters) - Atea Pharmaceuticals Inc AVIR.O:ATEA PHARMACEUTICALS APPOINTS HOWA","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nTUA47GFRM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COYA","BK4007","BK4139","AVIR"],"gpt_icon":0},{"id":"2528797011","title":"Atea Pharmaceuticals Inc: Authorized Repurchase of up to $25 Mln of Company's Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2528797011","media":"THOMSON REUTERS","labels":["buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528797011?lang=en_us&edition=fundamental","pubTime":"2025-04-17 19:00","pubTimestamp":1744887601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nTUA47GFRM:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"buyback","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["COYA","BK4007","BK4139","AVIR"],"gpt_icon":0},{"id":"2528179709","title":"Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2528179709","media":"THOMSON REUTERS","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528179709?lang=en_us&edition=fundamental","pubTime":"2025-04-17 19:00","pubTimestamp":1744887601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250417:nTUA47GFRM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","COYA","AVIR","BK4007"],"gpt_icon":0},{"id":"2528797700","title":"Press Release: Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2528797700","media":"Dow Jones","labels":["executive","shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528797700?lang=en_us&edition=fundamental","pubTime":"2025-04-17 19:00","pubTimestamp":1744887600,"startTime":"0","endTime":"0","summary":"Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program. Enters into Agreement with Bradley L. Radoff and Michael Torok. \"We are pleased to welcome Howard Berman to the Atea Board,\" said Jean-Pierre Sommadossi, Ph.D., Chief Executive Officer and Founder of Atea. \"We look forward to benefitting from Dr. Berman's industry experience and insights as we advance our global Phase 3 program evaluating the regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus  and our efforts to deliver value to Atea's shareholders.\". \"Atea's de-risked Phase 3 program with its potential best-in-class profile for the treatment of HCV has the potential to disrupt a multi-billion global market,\" said Dr. Berman. \"I look forward to joining the Board and working with my fellow directors on behalf of all Atea's shareholders.\". Atea also today announced that its Board has authorized, and will promptly begin executing upon, the repurchase of up","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","HBMD","COYA","AVIR","BK4211"],"gpt_icon":0},{"id":"2526610865","title":"Is Coya Therapeutics (COYA) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?","url":"https://stock-news.laohu8.com/highlight/detail?id=2526610865","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526610865?lang=en_us&edition=fundamental","pubTime":"2025-04-12 03:02","pubTimestamp":1744398140,"startTime":"0","endTime":"0","summary":"We recently published a list of Top 9 Healthcare Stocks to Buy According to Billionaire David Einhorn. In this article, we are going to take a look at where Coya Therapeutics, Inc.  stands against other top healthcare stocks to buy according to Billionaire David Einhorn.Wall Street has come down crashing on President Donald Trump’s sweeping tariffs, raising the risk of a trade war that could push the global economy into recession. Major equity indexes have recorded their worst days in years, with the S&P 500 slipping back into correction territory. Amid the bloodbath, the focus is slowly turning to defensive sectors poised to shrug off the long-term effects of the trade war.“We have reached the ‘Fartcoin’ stage of the market cycle,” Einhorn wrote in an investor letter obtained by CNBC. “Other than trading and speculation, it serves no other obvious purpose and fulfills no need that is not served elsewhere.”“Within the equity market, we continue to recommend that investors own the healt","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/coya-therapeutics-coya-top-healthcare-190220307.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".SPX","QID","SDS","VOO","GLRE","ESmain","BK4581","SH","QLD","NQmain","HCSG","SQQQ","IVV","BK4550","MNQmain","SPY","PSQ","BK4585",".IXIC","BK4139","BK4588","TQQQ","BK4534","USAW.SI","USJW.SI","NVIW.SI","TSYW.SI","BK4559","BK4504","COYA","OEF","BK4137","OEX","SSO"],"gpt_icon":1},{"id":"2524011384","title":"Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524011384","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524011384?lang=en_us&edition=fundamental","pubTime":"2025-04-01 20:15","pubTimestamp":1743509700,"startTime":"0","endTime":"0","summary":"Principal Investigator Alireza Faridar, M.D. to provide overview of data for the investigator-initiated \"Phase II Clinical Trial of Interleukin-2  in Patients with Mild to Moderate Alzheimer’s disease\". HOUSTON, April 01, 2025----Coya Therapeutics, Inc.  , a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell  function, announces that the principal investigator of a low-dose IL-2 Phase 2 study in Alzheimer’s disease , Alireza Faridar, M.D. from Houston Methodist Hospital, will be presenting previously announced progress to date at the ADPD 2025 conference in Vienna.The presentation, titled, \"A Phase II Clinical Trial of Interleukin-2  in Patients with Mild to Moderate Alzheimer’s disease,\" will take place on April 5, 2025.Forward-looking statements are subject to known and unknown risks, uncertainties, assumptions and other factors including, but not limited to, those","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/coya-therapeutics-selected-platform-presentation-121500422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LENZ","COYA"],"gpt_icon":0},{"id":"2522389555","title":"What Makes Coya Therapeutics, Inc. (COYA) a New Buy Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2522389555","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522389555?lang=en_us&edition=fundamental","pubTime":"2025-03-28 00:00","pubTimestamp":1743091210,"startTime":"0","endTime":"0","summary":"Coya Therapeutics, Inc.  could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 . This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Therefore, the Zacks rating upgrade for Coya Therapeutics, Inc. basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.For Coya Therapeutics, Inc. rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.This company is expected to earn -$1.36 per sh","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/makes-coya-therapeutics-inc-coya-160010576.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","COYA"],"gpt_icon":0},{"id":"2522058852","title":"Are Medical Stocks Lagging  Auna S.A. (AUNA) This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2522058852","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522058852?lang=en_us&edition=fundamental","pubTime":"2025-03-27 21:40","pubTimestamp":1743082808,"startTime":"0","endTime":"0","summary":"Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Auna S.A.  been one of those stocks this year?A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Auna S.A. is a member of our Medical group, which includes 1010 different companies and currently sits at #5 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Auna S.A. is currently sporting a Zacks Rank of #2 .One other Medical stock that has outperformed the sector so far this year is Coya Therapeutics,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medical-stocks-lagging-auna-auna-134008985.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AUNA","BK4185","BK4139","COYA"],"gpt_icon":0},{"id":"2522963805","title":"Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2522963805","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522963805?lang=en_us&edition=fundamental","pubTime":"2025-03-26 20:15","pubTimestamp":1742991300,"startTime":"0","endTime":"0","summary":"Regulatory T cell-derived exosomes  have demonstrated strong and consistent therapeutic potential in suppressing inflammation in preclinical models of neurodegenerative diseases as previously published here. Treg exosomes are end-stage differentiated, making them less likely to be affected by pro-inflammatory factors that may impact their suppressive function. The work planned includes GMP processes and manufacturing activities and the production of larger-scale clinical batches in the fourth quarter of 2025, in preparation for a first in human study. Coya’s previous research demonstrated that ex vivo expanded Treg exosomes express key immunoregulatory markers and effectively suppress pro-inflammatory responses in vitro. Treg exosomes are highly suppressive on pro-inflammatory macrophages and responder T cells. Additionally, Treg exosomes have advantages over Tregs in that they are taken up by myeloid cells that drive disease progression, and they are resistant to conversion to a non-s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/coya-therapeutics-reports-progress-academic-121500976.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065732104.USD","COYA","PRGS","LENZ","BK4139","BK4097"],"gpt_icon":0},{"id":"2520557924","title":"Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2520557924","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520557924?lang=en_us&edition=fundamental","pubTime":"2025-03-20 20:00","pubTimestamp":1742472059,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com?So should Coya Therapeutics  shareholders be worried about its cash burn?For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth . First, we'll determine its cash runway by comparing its cash burn with its cash reserves.Does Coya Therapeutics Have A Long Cash Runway?On this analysis of Coya Therapeutics' cash burn, we think its cash runway was rea","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/coya-therapeutics-nasdaq-coya-good-120059616.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BKPKM429.USD","BK4139","MNQmain","SQQQ","BK4112",".IXIC","COYA","QID","TSYW.SI","USJW.SI","BK4588","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","NDAQ","LU2095319765.USD","BK4585","NVIW.SI","LU2210149790.SGD","QLD","PSQ","TQQQ","LU2210150020.SGD","USAW.SI","IE00BGHQF748.EUR","NQmain"],"gpt_icon":1},{"id":"2520439968","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2520439968","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520439968?lang=en_us&edition=fundamental","pubTime":"2025-03-20 18:00","pubTimestamp":1742464800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Amprius Tech Inc                                4Q      (.11)  4:05 PM. ·Lands' End Inc.                                   4Q       .57   6:45 AM. ·Lennar Corp Class A                              1Q      1.70       AMC","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRAG","NKE","NKTX","OUST","LEN","DRI","JEF","CBUS","FBRX","DERM","IFRX","MBRX","BRNS","ASO","MGNX","MLKN","RUM","COYA","PL","TELA","SBS","SOWG","SKYE","SPRY","BCAB","BLRX","FLUX","ACRV","THRD","ALUR","CMC","CURV","TITN","BBNX","JKS","GDEV","MNSO","LVTX","MREO","KLC","CDLR","SLS","CELC","TH","LPTX","WOR","RLMD","PAYX"],"gpt_icon":1},{"id":"2520678944","title":"Press Release: Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2520678944","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520678944?lang=en_us&edition=fundamental","pubTime":"2025-03-18 20:15","pubTimestamp":1742300100,"startTime":"0","endTime":"0","summary":"Coya Therapeutics, Inc.  , a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell  function, provides a corporate update and announces its financial results for the year ended December 31, 2024.-- Announced significant improvements of inflammatory blood markers from an. exploratory Phase 2 study of low-dose interleukin-2  in patients. -- Announced that five of eight patients have been enrolled in the. investigator-initiated academic study of LD IL-2 + CTLA4-Ig combination. -- Announced positive results from an investigator initiated double-blind. moderate Alzheimer's Disease  at the Clinical Trials on Alzheimer's. Disease Conference  in Madrid. The study was titled, \"A Phase II. Clinical Trial of Interleukin-2  in Patients with Mild to Moderate. randomized, double-blind, placebo-controlled, Phase 2b trial of COYA-302. GLP-1 Receptor Agonist for treatment of inflammatory diseases and filing. of new intellectual property portfolio for the combin","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","COYA","BK4139"],"gpt_icon":0},{"id":"2516862684","title":"Analysts’ Top Healthcare Picks: Coya Therapeutics, Inc. (COYA), Jasper Therapeutics (JSPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2516862684","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516862684?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:00","pubTimestamp":1740999617,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Coya Therapeutics, Inc. (COYA – Research Report), Ja...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-coya-therapeutics-inc-coya-jasper-therapeutics-jspr?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-coya-therapeutics-inc-coya-jasper-therapeutics-jspr?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","JSPR","BK4139","HCSG","COYA"],"gpt_icon":0},{"id":"2509207040","title":"Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2509207040","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509207040?lang=en_us&edition=fundamental","pubTime":"2025-02-07 02:30","pubTimestamp":1738866612,"startTime":"0","endTime":"0","summary":"On Thursday, Coya Therapeutics, Inc. announced blood biomarker data from an investigator-initiated, 21-week, double-blind, placebo-controlled, exploratory Phase 2 study of LD IL-2 in patients with Alzheimer’s disease .Statistically significant reduced levels of proinflammatory markers were observed in patients receiving a five-day treatment of subcutaneous LD IL-2 on a monthly cycle in comparison to a biweekly 5-day administration or placebo.Also Read: EXCLUSIVE: Coya Therapeutics Expands Its Pipeline With Combo Therapy For Inflammatory Diseases. Lower blood levels of the proinflammatory chemokine  ligand 2   and proinflammatory cytokine IL-15  were statistically significant. A statistically significant increase in the anti-inflammatory cytokine IL-4  in patients receiving monthly cycles of LD IL-2 was observed compared to patients receiving a placebo.In addition, patients receiving LD IL-2 cycles at the higher biweekly frequency showed a smaller impact on these factors than monthly LD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/coya-therapeutics-alzheimers-candidate-shows-183012854.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSF","LENZ","COYA","BK4139"],"gpt_icon":0},{"id":"2509274482","title":"Coya Therapeutics up 8% on Positive Results From Mid-Stage Alzheimer’s Disease Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2509274482","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509274482?lang=en_us&edition=fundamental","pubTime":"2025-02-06 22:33","pubTimestamp":1738852429,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250206:nL4N3OX1NK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["COYA","BK4139"],"gpt_icon":0},{"id":"2509271164","title":"Coya Therapeutics Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2509271164","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509271164?lang=en_us&edition=fundamental","pubTime":"2025-02-06 22:09","pubTimestamp":1738850940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/COYA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 06, 2025 09:09 ET (14:09 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","COYA"],"gpt_icon":0},{"id":"2509828276","title":"BRIEF-Coya Therapeutics Inc Reports Significant Improvement In Inflammatory Markers In Alzheimer's Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2509828276","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509828276?lang=en_us&edition=fundamental","pubTime":"2025-02-06 21:34","pubTimestamp":1738848846,"startTime":"0","endTime":"0","summary":"BRIEF-Coya Therapeutics Inc Reports Significant Improvement In Inflammatory Markers In Alzheimer's PatientsFeb 6 (Reuters) - Coya Therapeutics Inc COYA.O:COYA THERAPEUTICS INC - REPORTS SIGNIFICANT IM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250206:nFWN3OX0UC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COYA","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":56,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/COYA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"COYA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"COYA\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2,"buy":0.8,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8,"analysts":5,"updateTime":1743048000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/COYA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"COYA","date":"2025-04-17","current":-5.866927,"percent":0.573503,"low":-18.170827,"twenty":-10.3533,"median":-7.730177,"eighty":-3.639844,"high":-2.532969,"avg":-7.456036,"sd":3.905291,"marketCap":87304489},"quantilePoints":[{"date":"2022-12-30","current":-4.259584,"twenty":-5.088378,"median":-4.673981,"eighty":-4.199135,"marketCap":45862003},{"date":"2023-01-06","current":-4.198451,"twenty":-4.75686,"median":-4.211892,"eighty":-4.164199,"marketCap":45203803},{"date":"2023-01-13","current":-4.315322,"twenty":-4.421315,"median":-4.259584,"eighty":-4.180381,"marketCap":46462126},{"date":"2023-01-20","current":-4.288262,"twenty":-4.396143,"median":-4.253021,"eighty":-4.180381,"marketCap":46170776},{"date":"2023-01-27","current":-4.181765,"twenty":-4.394298,"median":-4.256303,"eighty":-4.180658,"marketCap":45024142},{"date":"2023-02-03","current":-3.675163,"twenty":-4.351211,"median":-4.234322,"eighty":-4.117451,"marketCap":39569675},{"date":"2023-02-10","current":-3.877804,"twenty":-4.30991,"median":-4.190108,"eighty":-3.84096,"marketCap":41751462},{"date":"2023-02-17","current":-3.850171,"twenty":-4.288262,"median":-4.180381,"eighty":-3.855698,"marketCap":41453946},{"date":"2023-02-24","current":-3.684374,"twenty":-4.288262,"median":-4.153411,"eighty":-3.785695,"marketCap":39668848},{"date":"2023-03-03","current":-4.089655,"twenty":-4.270282,"median":-4.071233,"eighty":-3.770128,"marketCap":44032421},{"date":"2023-03-10","current":-4.23703,"twenty":-4.288262,"median":-4.153411,"eighty":-3.785695,"marketCap":45619175},{"date":"2023-03-17","current":-3.905437,"twenty":-4.29377,"median":-4.180381,"eighty":-3.822538,"marketCap":42048978},{"date":"2023-03-24","current":-3.73964,"twenty":-4.288262,"median":-4.108461,"eighty":-3.73964,"marketCap":40263880},{"date":"2023-03-31","current":-3.218192,"twenty":-4.288262,"median":-4.048207,"eighty":-3.707402,"marketCap":39406041},{"date":"2023-04-06","current":-3.099387,"twenty":-4.273878,"median":-3.979124,"eighty":-3.684448,"marketCap":37951295},{"date":"2023-04-14","current":-3.233436,"twenty":-4.261724,"median":-3.905437,"eighty":-3.63832,"marketCap":39592701},{"date":"2023-04-21","current":-3.534032,"twenty":-4.256278,"median":-3.877804,"eighty":-3.512909,"marketCap":43273430},{"date":"2023-04-28","current":-3.753386,"twenty":-4.253993,"median":-3.850523,"eighty":-3.541339,"marketCap":45959367},{"date":"2023-05-05","current":-4.053981,"twenty":-4.248953,"median":-3.850876,"eighty":-3.590423,"marketCap":49640095},{"date":"2023-05-12","current":-3.858435,"twenty":-4.25448,"median":-3.877804,"eighty":-3.627267,"marketCap":51231762},{"date":"2023-05-19","current":-4.210564,"twenty":-4.257931,"median":-3.905437,"eighty":-3.63832,"marketCap":55907282},{"date":"2023-05-26","current":-3.109224,"twenty":-4.25448,"median":-3.877804,"eighty":-3.560217,"marketCap":41283847},{"date":"2023-06-02","current":-3.431385,"twenty":-4.251665,"median":-3.850876,"eighty":-3.429011,"marketCap":45561450},{"date":"2023-06-09","current":-3.611196,"twenty":-4.244399,"median":-3.84096,"eighty":-3.421013,"marketCap":47948950},{"date":"2023-06-16","current":-3.618688,"twenty":-4.23703,"median":-3.850171,"eighty":-3.424798,"marketCap":48048429},{"date":"2023-06-23","current":-3.566243,"twenty":-4.23703,"median":-3.830566,"eighty":-3.428417,"marketCap":47352075},{"date":"2023-06-30","current":-3.146685,"twenty":-4.23703,"median":-3.818461,"eighty":-3.418016,"marketCap":41781243},{"date":"2023-07-07","current":-3.071764,"twenty":-4.235405,"median":-3.785695,"eighty":-3.362458,"marketCap":40786451},{"date":"2023-07-14","current":-3.041795,"twenty":-4.228928,"median":-3.76675,"eighty":-3.288681,"marketCap":40388534},{"date":"2023-07-21","current":-2.981859,"twenty":-4.224887,"median":-3.746054,"eighty":-3.233436,"marketCap":39592701},{"date":"2023-07-28","current":-3.019319,"twenty":-4.216174,"median":-3.721218,"eighty":-3.218192,"marketCap":40090097},{"date":"2023-08-04","current":-2.876969,"twenty":-4.203296,"median":-3.712007,"eighty":-3.16841,"marketCap":38199993},{"date":"2023-08-11","current":-2.839996,"twenty":-4.188439,"median":-3.693585,"eighty":-3.145639,"marketCap":36807285},{"date":"2023-08-18","current":-2.54832,"twenty":-4.180935,"median":-3.684466,"eighty":-3.105289,"marketCap":33027077},{"date":"2023-08-25","current":-2.709509,"twenty":-4.180381,"median":-3.675163,"eighty":-3.078507,"marketCap":35116139},{"date":"2023-09-01","current":-2.709509,"twenty":-4.180381,"median":-3.63832,"eighty":-3.046291,"marketCap":35116139},{"date":"2023-09-08","current":-3.691995,"twenty":-4.169593,"median":-3.63832,"eighty":-3.044792,"marketCap":47849471},{"date":"2023-09-15","current":-3.546157,"twenty":-4.135431,"median":-3.63832,"eighty":-3.058278,"marketCap":45959367},{"date":"2023-09-21","current":-3.031887,"twenty":-4.1047,"median":-3.619293,"eighty":-3.053783,"marketCap":39294264},{"date":"2023-09-29","current":-3.162374,"twenty":-4.08252,"median":-3.599887,"eighty":-3.071764,"marketCap":40985409},{"date":"2023-10-06","current":-2.594374,"twenty":-4.053747,"median":-3.556227,"eighty":-3.033869,"marketCap":33623952},{"date":"2023-10-13","current":-3.745724,"twenty":-4.05097,"median":-3.54621,"eighty":-3.041795,"marketCap":48545825},{"date":"2023-10-20","current":-3.937616,"twenty":-4.036232,"median":-3.575206,"eighty":-3.043294,"marketCap":51032803},{"date":"2023-10-27","current":-3.645941,"twenty":-4.021495,"median":-3.590557,"eighty":-3.046291,"marketCap":47252596},{"date":"2023-11-03","current":-3.684319,"twenty":-3.985193,"median":-3.599887,"eighty":-3.062774,"marketCap":47749992},{"date":"2023-11-10","current":-3.870934,"twenty":-4.021495,"median":-3.619293,"eighty":-3.071764,"marketCap":47850465},{"date":"2023-11-17","current":-4.057134,"twenty":-4.055242,"median":-3.63832,"eighty":-3.071764,"marketCap":50152180},{"date":"2023-11-24","current":-4.259991,"twenty":-4.064747,"median":-3.645941,"eighty":-3.07577,"marketCap":52659789},{"date":"2023-12-01","current":-4.324905,"twenty":-4.105159,"median":-3.675163,"eighty":-3.082268,"marketCap":53462223},{"date":"2023-12-08","current":-5.631302,"twenty":-4.180381,"median":-3.684374,"eighty":-3.084048,"marketCap":69611225},{"date":"2023-12-15","current":-7.875233,"twenty":-4.205719,"median":-3.689056,"eighty":-3.088687,"marketCap":97349529},{"date":"2023-12-22","current":-7.933482,"twenty":-4.235947,"median":-3.693585,"eighty":-3.093672,"marketCap":98069570},{"date":"2023-12-29","current":-8.842163,"twenty":-4.23703,"median":-3.709704,"eighty":-3.09424,"marketCap":109302208},{"date":"2024-01-05","current":-7.793685,"twenty":-4.253993,"median":-3.715021,"eighty":-3.09424,"marketCap":96341472},{"date":"2024-01-12","current":-7.877698,"twenty":-4.259991,"median":-3.721218,"eighty":-3.097328,"marketCap":97379997},{"date":"2024-01-19","current":-6.724011,"twenty":-4.272114,"median":-3.742682,"eighty":-3.100019,"marketCap":83118725},{"date":"2024-01-26","current":-6.99204,"twenty":-4.300291,"median":-3.753386,"eighty":-3.10427,"marketCap":86431950},{"date":"2024-02-02","current":-7.213454,"twenty":-4.321125,"median":-3.76675,"eighty":-3.109224,"marketCap":89168961},{"date":"2024-02-09","current":-7.935965,"twenty":-4.359055,"median":-3.785695,"eighty":-3.121212,"marketCap":98100263},{"date":"2024-02-16","current":-8.91485,"twenty":-4.404211,"median":-3.812795,"eighty":-3.139255,"marketCap":110200736},{"date":"2024-02-23","current":-10.04523,"twenty":-4.438913,"median":-3.822509,"eighty":-3.140292,"marketCap":124173901},{"date":"2024-03-01","current":-10.476406,"twenty":-5.628056,"median":-3.830566,"eighty":-3.144593,"marketCap":129503871},{"date":"2024-03-08","current":-10.441446,"twenty":-5.900696,"median":-3.837832,"eighty":-3.146685,"marketCap":129071712},{"date":"2024-03-15","current":-11.653399,"twenty":-6.72168,"median":-3.850171,"eighty":-3.146685,"marketCap":144053250},{"date":"2024-03-22","current":-18.042053,"twenty":-6.870845,"median":-3.854655,"eighty":-3.146752,"marketCap":144116957},{"date":"2024-03-28","current":-17.568699,"twenty":-6.99204,"median":-3.858435,"eighty":-3.147022,"marketCap":140335887},{"date":"2024-04-05","current":-16.744948,"twenty":-7.213454,"median":-3.877804,"eighty":-3.154698,"marketCap":133755895},{"date":"2024-04-12","current":-16.708387,"twenty":-7.481482,"median":-3.895399,"eighty":-3.162374,"marketCap":133463852},{"date":"2024-04-19","current":-15.428751,"twenty":-7.933482,"median":-3.905437,"eighty":-3.168361,"marketCap":123242331},{"date":"2024-04-26","current":-15.41047,"twenty":-7.947618,"median":-3.91531,"eighty":-3.168442,"marketCap":123096309},{"date":"2024-05-03","current":-16.050288,"twenty":-8.108228,"median":-3.925864,"eighty":-3.184145,"marketCap":128207070},{"date":"2024-05-10","current":-15.465312,"twenty":-8.157379,"median":-3.945867,"eighty":-3.193076,"marketCap":123534375},{"date":"2024-05-17","current":-12.046492,"twenty":-8.434421,"median":-4.006757,"eighty":-3.19913,"marketCap":124118462},{"date":"2024-05-24","current":-12.027546,"twenty":-8.842163,"median":-4.037702,"eighty":-3.208428,"marketCap":123923260},{"date":"2024-05-31","current":-11.153807,"twenty":-9.523158,"median":-4.053396,"eighty":-3.216239,"marketCap":114920875},{"date":"2024-06-07","current":-10.311731,"twenty":-10.30363,"median":-4.063993,"eighty":-3.218192,"marketCap":106244729},{"date":"2024-06-14","current":-11.493592,"twenty":-10.481448,"median":-4.089655,"eighty":-3.221544,"marketCap":118421776},{"date":"2024-06-21","current":-9.425336,"twenty":-10.483969,"median":-4.100207,"eighty":-3.22689,"marketCap":97111945},{"date":"2024-06-28","current":-8.996912,"twenty":-10.491151,"median":-4.108461,"eighty":-3.230001,"marketCap":92697765},{"date":"2024-07-05","current":-8.819633,"twenty":-10.481448,"median":-4.153411,"eighty":-3.232684,"marketCap":90871208},{"date":"2024-07-12","current":-10.592423,"twenty":-10.481448,"median":-4.180381,"eighty":-3.233436,"marketCap":109136778},{"date":"2024-07-15","current":-11.065167,"twenty":-10.491151,"median":-4.180381,"eighty":-3.233436,"marketCap":114007596},{"date":"2024-08-02","current":-9.957173,"twenty":-10.489011,"median":-4.181073,"eighty":-3.233436,"marketCap":102591615},{"date":"2024-08-09","current":-9.277604,"twenty":-10.476406,"median":-4.210564,"eighty":-3.233436,"marketCap":95589814},{"date":"2024-08-16","current":-7.550677,"twenty":-10.441446,"median":-4.229827,"eighty":-3.251575,"marketCap":76258753},{"date":"2024-08-23","current":-9.374293,"twenty":-10.311731,"median":-4.23703,"eighty":-3.274051,"marketCap":94676535},{"date":"2024-08-30","current":-8.852829,"twenty":-10.301605,"median":-4.249631,"eighty":-3.28015,"marketCap":89409963},{"date":"2024-09-06","current":-9.133154,"twenty":-10.286069,"median":-4.257518,"eighty":-3.290318,"marketCap":92241126},{"date":"2024-09-13","current":-8.982442,"twenty":-10.167203,"median":-4.259991,"eighty":-3.294066,"marketCap":90718995},{"date":"2024-09-20","current":-9.374293,"twenty":-10.063875,"median":-4.267746,"eighty":-3.325565,"marketCap":94676535},{"date":"2024-09-27","current":-9.46472,"twenty":-10.033878,"median":-4.288262,"eighty":-3.333863,"marketCap":95589814},{"date":"2024-10-04","current":-10.301173,"twenty":-10.081747,"median":-4.299205,"eighty":-3.345975,"marketCap":104037640},{"date":"2024-10-11","current":-10.45942,"twenty":-10.301259,"median":-4.315322,"eighty":-3.366953,"marketCap":105635877},{"date":"2024-10-18","current":-12.388535,"twenty":-10.462817,"median":-4.33302,"eighty":-3.382641,"marketCap":125119151},{"date":"2024-10-25","current":-14.93557,"twenty":-10.558363,"median":-4.357362,"eighty":-3.391203,"marketCap":150843162},{"date":"2024-10-31","current":-10.029891,"twenty":-10.623264,"median":-4.367898,"eighty":-3.402403,"marketCap":101297804},{"date":"2024-11-08","current":-10.271752,"twenty":-10.614867,"median":-4.40398,"eighty":-3.415739,"marketCap":109897843},{"date":"2024-11-15","current":-9.688453,"twenty":-10.599507,"median":-4.432103,"eighty":-3.422453,"marketCap":103657107},{"date":"2024-11-22","current":-9.494429,"twenty":-10.566878,"median":-5.088378,"eighty":-3.426607,"marketCap":101581241},{"date":"2024-11-29","current":-10.181526,"twenty":-10.529794,"median":-5.623188,"eighty":-3.429604,"marketCap":108932515},{"date":"2024-12-06","current":-9.338271,"twenty":-10.495432,"median":-5.858502,"eighty":-3.46435,"marketCap":99910497},{"date":"2024-12-13","current":-9.088417,"twenty":-10.483969,"median":-5.907187,"eighty":-3.516795,"marketCap":97237306},{"date":"2024-12-20","current":-8.057772,"twenty":-10.469612,"median":-6.712358,"eighty":-3.52129,"marketCap":86210395},{"date":"2024-12-27","current":-8.541863,"twenty":-10.455825,"median":-6.793932,"eighty":-3.523838,"marketCap":91389702},{"date":"2025-01-03","current":-8.916643,"twenty":-10.441446,"median":-6.852199,"eighty":-3.534032,"marketCap":95399488},{"date":"2025-01-10","current":-9.478813,"twenty":-10.430887,"median":-6.957079,"eighty":-3.543732,"marketCap":101414166},{"date":"2025-01-17","current":-8.744869,"twenty":-10.348577,"median":-6.99204,"eighty":-3.546199,"marketCap":93561669},{"date":"2025-01-24","current":-9.119649,"twenty":-10.325731,"median":-7.13188,"eighty":-3.555389,"marketCap":97571455},{"date":"2025-01-31","current":-9.150881,"twenty":-10.318171,"median":-7.256788,"eighty":-3.564349,"marketCap":97905604},{"date":"2025-02-07","current":-10.931086,"twenty":-10.318171,"median":-7.341641,"eighty":-3.568008,"marketCap":116952087},{"date":"2025-02-14","current":-10.681233,"twenty":-10.383279,"median":-7.550677,"eighty":-3.569184,"marketCap":114278896},{"date":"2025-02-21","current":-9.634972,"twenty":-10.398268,"median":-7.746602,"eighty":-3.574001,"marketCap":103084910},{"date":"2025-02-28","current":-10.509459,"twenty":-10.398268,"median":-7.876466,"eighty":-3.588691,"marketCap":112441077},{"date":"2025-03-07","current":-9.822362,"twenty":-10.45223,"median":-7.935965,"eighty":-3.604411,"marketCap":105089803},{"date":"2025-03-14","current":-10.119063,"twenty":-10.461335,"median":-7.947618,"eighty":-3.614193,"marketCap":108264217},{"date":"2025-03-21","current":-7.264209,"twenty":-10.461335,"median":-7.947618,"eighty":-3.619172,"marketCap":108097143},{"date":"2025-03-28","current":-7.743894,"twenty":-10.45223,"median":-7.935965,"eighty":-3.621104,"marketCap":115235236},{"date":"2025-04-04","current":-6.855987,"twenty":-10.436166,"median":-7.877698,"eighty":-3.629076,"marketCap":102022487},{"date":"2025-04-11","current":-5.540987,"twenty":-10.398268,"median":-7.770143,"eighty":-3.63832,"marketCap":82454240},{"date":"2025-04-17","current":-5.866927,"twenty":-10.3533,"median":-7.730177,"eighty":-3.639844,"marketCap":87304489}],"updateTime":1745273673020}}}